These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29530712)

  • 41. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
    Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
    Rangel-Barajas C; Silva I; Lopéz-Santiago LM; Aceves J; Erlij D; Florán B
    Neurobiol Dis; 2011 Jan; 41(1):51-61. PubMed ID: 20736067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
    Huot P; Johnston TH; Koprich JB; Espinosa MC; Reyes MG; Fox SH; Brotchie JM
    Behav Pharmacol; 2015 Feb; 26(1-2):101-8. PubMed ID: 25303957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?
    Laloux C; Gouel F; Lachaud C; Timmerman K; Do Van B; Jonneaux A; Petrault M; Garcon G; Rouaix N; Moreau C; Bordet R; Duce JA; Devedjian JC; Devos D
    Neurobiol Dis; 2017 Jul; 103():24-31. PubMed ID: 28363801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M; Lindgren HS; Lundblad M; Stancampiano R; Fadda F; Cenci MA
    J Neurochem; 2006 Mar; 96(6):1718-27. PubMed ID: 16539687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
    Huot P
    J Neurol Sci; 2015 Apr; 351(1-2):9-12. PubMed ID: 25758471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
    Li L; Sagot B; Zhou FM
    Brain Res; 2015 Jul; 1615():12-21. PubMed ID: 25960345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
    Sano H; Nambu A
    Neurochem Int; 2019 Mar; 124():171-180. PubMed ID: 30639196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.